MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
PTC Therapeutics EPS Ratio 2011-2025 | PTCT
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio PTC Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -5.18 | 220 | 23.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 220 | -8.37 | 13 |
Quarterly EPS Ratio PTC Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.2 | -0.83 | 11.1 | - | -1.39 | -1.29 | -1.2 | - | -1.76 | -2.66 | -1.88 | - | -1.53 | -2.13 | -1.78 | - | -1.89 | -1.68 | -1.83 | -1.08 | -1.03 | -2.78 | -1.81 | -1.37 | -1.06 | -0.75 | -1.29 | 0.96 | -1.06 | -0.21 | -0.46 | 0.03 | -0.82 | -0.44 | -0.85 | -0.78 | -1.03 | -1.14 | -1.22 | -1.5 | -1.27 | -1.14 | -1.15 | -0.84 | -0.93 | -0.86 | -0.58 | -0.75 | -0.19 | -5.51 | -6.53 K | -1.38 K | -1.61 K | 168 | -5.99 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 168 | -6.53 K | -302 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-0.44 | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
-1.71 | $ 3.04 | 4.83 % | $ 235 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-87.4 | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-8.28 | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioVie
BIVI
|
-12.1 | $ 1.27 | -3.05 % | $ 1.88 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
Bellicum Pharmaceuticals
BLCM
|
-0.81 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-1.42 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | USA |
 |
Catalyst Biosciences
CBIO
|
-1.41 | $ 12.37 | 2.06 % | $ 814 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-2.67 | - | - | $ 7.29 B | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Celldex Therapeutics
CLDX
|
-2.45 | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M | Britain |
 |
Celsion Corporation
CLSN
|
-1.62 | - | -6.63 % | $ 13.9 M | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 95.03 | 0.95 % | $ 27.2 B | Germany |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
3.29 | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
1.35 | $ 83.59 | 1.95 % | $ 8.63 B | USA |
 |
Anika Therapeutics
ANIK
|
-5.64 | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
CorMedix
CRMD
|
-0.91 | $ 12.19 | 1.75 % | $ 621 M | USA |
 |
Cortexyme
CRTX
|
-0.84 | - | -1.05 % | $ 67.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 0.18 | -25.03 % | $ 392 M |  Israel |
 |
CTI BioPharma Corp.
CTIC
|
-0.81 | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-10.1 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
4.98 | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-2.16 | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
0.08 | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | USA |